Sugi Predict

Sugi Predict / Compounds / SCHEMBL868675

SCHEMBL868675

SCHEMBL868675

CC(C)(C)OC(=O)N1CCc2cc(B3OC(C)(C)C(C)(C)O3)ccc21

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 1/20 0.43
▸ GPR119 Q8TDV5 6/20 0.42
▸ PRMT5 O14744 1/20 0.41
▸ WDR77 Q9BQA1 1/20 0.41
▸ ABHD6 Q9BV23 1/20 0.41
▸ DHODH Q02127 1/20 0.41
▸ BRD4 O60885 1/20 0.39
▸ BACE1 P56817 1/20 0.39
▸ BACE2 Q9Y5Z0 1/20 0.39
▸ CHRM4 P08173 1/20 0.39
▸ DRD2 P14416 1/20 0.39
▸ HTR7 P34969 1/20 0.39
▸ AAK1 Q2M2I8 1/20 0.39
▸ NOTUM Q6P988 2/20 0.38
▸ ESR2 Q92731 1/20 0.38
▸ MPO P05164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31167558 1.00 USP30 (0.43) USP30GPR119PRMT5WDR77ABHD6
SCHEMBL29782709 0.93 BRD4 (0.46) USP30GPR119PRMT5WDR77DHODH
SCHEMBL17700030 0.93 BRD4 (0.46) USP30GPR119PRMT5WDR77DHODH
SCHEMBL29513830 0.91 CHRM4 (0.45) USP30GPR119PRMT5WDR77DHODH
SCHEMBL594429 0.91 CHRM4 (0.45) USP30GPR119PRMT5WDR77DHODH
SCHEMBL30163103 0.86 USP30 (0.42) USP30GPR119PRMT5WDR77BACE1
SCHEMBL29218282 0.86 USP30 (0.42) USP30GPR119PRMT5WDR77BACE1
SCHEMBL22815788 0.85 MPO (0.42) USP30GPR119PRMT5WDR77DHODH
SCHEMBL30254676 0.84 USP30 (0.42) USP30PRMT5WDR77BRD4BACE1
SCHEMBL595110 0.84 USP30 (0.42) USP30PRMT5WDR77BRD4BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260055097-A9 NRF2 PROTEIN DEGRADERS GANYMEDE ONCOLOGY INC (US) 2026-02-26 — — US disclosed
EP-3717459-B1 COMPOUNDS STEP PHARMA S A S (FR) 2026-01-21 — — EP disclosed
US-12503466-B2 Aminothiazole compounds as inhibitors of CTPS1 STEP PHARMA S.A.S. (FR) 2025-12-23 — — US disclosed
US-20250145611-A1 NRF2 PROTEIN DEGRADERS GANYMEDE ONCOLOGY, INC. 2025-05-08 — — US disclosed
EP-4543439-A2 NRF2 PROTEIN DEGRADERS Ganymede Oncology, Inc. (US) 2025-04-30 — — EP disclosed
WO-2024083111-A1 NOVEL HETEROCYCLIC COMPOUNDS 首药控股(北京)股份有限公司 2024-04-25 — — WO disclosed
US-20240043420-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN INC. 2024-02-08 — — US disclosed
US-20240010645-A1 Aminothiazole Compounds as Inhibitors of CTPS1 STEP PHARMA S.A.S. (FR) 2024-01-11 — — US disclosed
WO-2024006742-A2 NRF2 PROTEIN DEGRADERS DRACEN PHARMACEUTICALS, INC. (US) 2024-01-04 — — WO disclosed
US-11780821-B2 Inhibitors of fibroblast activation protein Praxis Biotech LLC (US) 2023-10-10 — — US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 — — EP disclosed
US-20080255184-A1 Thienopyridine B-Raf Kinase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-10-16 — — US disclosed
EP-1951728-A2 THIENOPYRIDINE B-RAF KINASE INHIBITORS SmithKline Beecham Corporation (US) 2008-08-06 — — EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 — — US disclosed
WO-2007056625-A2 THIENOPYRIDINE B-RAF KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-05-18 — — WO disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 — — US disclosed
EP-1648905-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS Abbott Laboratories (US) 2006-04-26 — — EP disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 — — US disclosed
WO-2005010009-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2005-02-03 — — WO disclosed
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES 2005-02-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503466-B2 Aminothiazole compounds as inhibitors of CTPS1 CTPS1, CTPS2, TBXAS1 USP30 3549/4885GPR119 2998/4885PRMT5 2033/4885
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK USP30 3936/4885GPR119 2320/4885PRMT5 433/4885
US-20240043420-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ABL1, ABL2, BCR USP30 2047/4885GPR119 2929/4885PRMT5 150/4885
US-20080255184-A1 Thienopyridine B-Raf Kinase Inhibitors BRAF, RAF1, ARAF USP30 3600/4885GPR119 1736/4885PRMT5 1068/4885
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK USP30 3936/4885GPR119 2320/4885PRMT5 433/4885
US-11780821-B2 Inhibitors of fibroblast activation protein FAP, FIBP, FRS2 USP30 1920/4885GPR119 3934/4885PRMT5 2752/4885
US-20260055097-A9 NRF2 PROTEIN DEGRADERS KEAP1, NFE2L2, NFE2 USP30 660/4885GPR119 3733/4885PRMT5 2633/4885
US-20250145611-A1 NRF2 PROTEIN DEGRADERS KEAP1, NFE2L2, NFE2 USP30 540/4885GPR119 2360/4885PRMT5 813/4885
US-20240010645-A1 Aminothiazole Compounds as Inhibitors of CTPS1 CTPS1, CTPS2, TBXAS1 USP30 3549/4885GPR119 2998/4885PRMT5 2033/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK USP30 3936/4885GPR119 2320/4885PRMT5 433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.